Article

IntraLase sales on rise for all-laser flap device

Irvine, CA-IntraLase Corp. is seeing greater acceptance of its all-laser technology, reporting its lasers were used 136% more during the fourth quarter of 2003 than in the same quarter a year ago.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
Related Content
Beacon Therapeutics completes enrollment in phase 2/3 VISTA trial
July 8th 2025

Beacon Therapeutics completes enrollment in phase 2/3 VISTA trial

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Boehringer Ingelheim launches phase 2 study of oral therapy for diabetic macular edema
July 8th 2025

Boehringer Ingelheim launches phase 2 study of oral therapy for diabetic macular edema

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

PER-001 shows vision restoration in glaucoma and DR in phase 2a trials
July 7th 2025

PER-001 shows vision restoration in glaucoma and DR in phase 2a trials

4DMT accelerating 4D-150 4FRONT phase 3 program, laying off 25% of staff
July 7th 2025

4DMT accelerating 4D-150 4FRONT phase 3 program, laying off 25% of staff

© 2025 MJH Life Sciences

All rights reserved.